Few people outside the medical profession have even heard of Sepsis, the third most common cause of death for hospitalized patients in the developed world, behind heart disease and cancer. 30% of […]
An engineering approach to translational medicine
The mechanisms that drive disease have long confounded the medical industry. How much of a part does genetics play? How does the patient’s lifestyle influence his or her risk of developing cancer? What makes one patient respond favorably to a particular treatment, while another suffers severe side effects?
Scientists developing one-size-fits-all bioterrorism vaccine
Scientists at the Scripps Research Institute are developing a new method of vaccination that could potentially be used to provide instantaneous protection whether the target is a cancer cell, flu virus, or […]
An unusual source for antibody–based therapeutics
The future of medicine may lie in an unexpected place: within the immune system of a llama. The Wall Street Journal reports that scientists in Brussels are using llamas to develop antibody–based […]
Study Links Smoking to Most Male Cancer Deaths, Not Just those from Lung Cancer
A new study links smoking to a much greater percentage of deaths among men from all types cancer including lung cancer, suggesting that increased tobacco control efforts could save more lives than […]
Top 10 Medical Innovations for 2009
The Cleveland Clinic has unveiled its latest Top 10 Medical Innovations list, highlighting technologies that are expected to have a big impact in 2009. Announced during Cleveland Clinic’s 2008 Medical Innovation Summit,, […]
Insight Dx Prostate Profile: Clarient Launches Gene Expression Test for Prostate Cancer
Clarient has launched a new gene expression diagnostic for prostate cancer, the Insight Dx Prostate Profile (Insight). The test, developed in conjunction with Health Discovery Corp., uses expression values from four genes […]
AngioDynamics: No Growth Expected in 2009
It’s been a roller coaster of a year for AngioDynamics. In the past, I’ve professed my high opinion of the company. I still like ANGO and I think it’s fairly valued, but […]
